Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Clin Genitourin Cancer. 2014 Jun;12(3):190-5. doi: 10.1016/j.clgc.2013.11.004. Epub 2013 Nov 12.
The aim of this study was to present survival outcomes and identify prognostic factors in patients undergoing radical cystectomy (RC) for urothelial bladder cancer (UBC) in a homogeneous surgery-only series.
Patients who underwent RC for UBC with intent-to-cure between January 1998 and December 2010 without neoadjuvant or adjuvant treatment were included in this retrospective study. Clinical and histopathologic data were collected and institutional review board approval was obtained. Outcomes of interest were 30-day mortality (30dM), RFS, and OS. Univariable and multivariable analysis were performed. Median follow-up was 9.1 years.
Two hundred forty-five patients were included with a median age of 65 years (range, 34-92 years). 30dM rate was in 5 out of 245 patients (2.0%) and 5-year RFS and OS rates were 67% and 58%, respectively. A total of 223 patients (91%) underwent lymph node (LN) dissection. Median number of removed and positive LNs were 9 and 1.5, respectively. Variables independently associated with decreased OS and RFS were tumor stage and LN status. In addition, positive soft tissue surgical margin (STSM) status was independently associated with decreased OS. In LN-positive patients, presence of extranodal extension (ENE) was associated with decreased RFS (39.7% vs. 7.3%; P = .005).
Radical cystectomy for UBC was associated with low perioperative mortality rate and provided 5-year disease control in approximately two-thirds of patients. Independent prognostic factors included tumor stage, LN status (RFS and OS), and STSM status (OS). Presence of ENE in LN-positive patients was univariably associated with decreased RFS and OS.
本研究旨在展示生存结果,并确定接受根治性膀胱切除术(RC)治疗尿路上皮膀胱癌(UBC)患者的预后因素,这些患者均为单一手术治疗,且无新辅助或辅助治疗。
本回顾性研究纳入了 1998 年 1 月至 2010 年 12 月期间因 UBC 接受 RC 治疗且具有治愈意图的患者。收集了临床和组织病理学数据,并获得了机构审查委员会的批准。研究的主要终点是 30 天死亡率(30dM)、无复发生存率(RFS)和总生存率(OS)。进行了单变量和多变量分析。中位随访时间为 9.1 年。
共纳入 245 例患者,中位年龄为 65 岁(范围:34-92 岁)。245 例患者中,有 5 例(2.0%)出现 30dM,5 年 RFS 和 OS 率分别为 67%和 58%。223 例(91%)患者行淋巴结(LN)清扫术,中位清扫 LN 数和阳性 LN 数分别为 9 枚和 1.5 枚。与 OS 和 RFS 降低相关的变量包括肿瘤分期和 LN 状态。此外,阳性软组织切缘(STSM)状态与 OS 降低独立相关。在 LN 阳性患者中,存在结外扩展(ENE)与 RFS 降低相关(39.7% vs. 7.3%;P=0.005)。
RC 治疗 UBC 的围手术期死亡率较低,约三分之二的患者在 5 年内得到了疾病控制。独立的预后因素包括肿瘤分期、LN 状态(RFS 和 OS)和 STSM 状态(OS)。在 LN 阳性患者中,ENE 的存在与 RFS 和 OS 的降低独立相关。